RxDoctor Payments Data

Celestina Peters

Family · Winter Park, FLNPI 1487017422

Payments from drug & device makers

$1,647in general payments, 2019–2025

Across 63 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$439
  • Teva Pharmaceuticals USA, Inc.$390
  • Acadia Pharmaceuticals Inc$327
  • Alpha Cognition USA, Inc.$235
  • Otsuka America Pharmaceutical, Inc.$164
  • Avanir Pharmaceuticals, Inc.$40
  • plus $53 from 2 others

What the payments were for

  • Food & beverage$1,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,647 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$84,885
Medicare patients
389
Services billed
861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine159$247,883
Invega SustennaPaliperidone Palmitate12$43,999
Divalproex Sodium307$12,078
Trazodone Hcl330$4,933
Quetiapine Fumarate175$4,161
Mirtazapine94$3,684
Duloxetine Hcl59$2,830
Sertraline Hcl163$1,796
Buspirone Hcl69$1,457
Clozapine15$1,044
Valproic AcidValproic Acid (As Sodium Salt)26$785
Olanzapine OdtOlanzapine14$672
Lorazepam54$568
Estradiol29$485
Escitalopram Oxalate18$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$40$247,883159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.

Other family in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →